Terms: = Lung cancer AND XPO1, DKFZp686B1823, 7514, ENSG00000082898, O14980, CRM1 AND Treatment
11 results:
1. Cisplatin Dependent Secretion of Immunomodulatory High Mobility Group Box 1 (HMGB1) Protein from lung cancer Cells.
Gillespie KP; Pirnie R; Mesaros C; Blair IA
Biomolecules; 2023 Aug; 13(9):. PubMed ID: 37759736
[TBL] [Abstract] [Full Text] [Related]
2. xpo1-Mediated EIF1AX Cytoplasmic Relocation Promotes Tumor Migration and Invasion in Endometrial Carcinoma.
Ye Y; Lv C; Sun J; Lin Z; Liu Y; Huang Y; Chen Y; Li H; Lian X; Jiang X; Zhang S; Wang S
Oxid Med Cell Longev; 2022; 2022():1361135. PubMed ID: 36589683
[TBL] [Abstract] [Full Text] [Related]
3. The efficacy of selinexor (KPT-330), an xpo1 inhibitor, on non-hematologic cancers: a comprehensive review.
Landes JR; Moore SA; Bartley BR; Doan HQ; Rady PL; Tyring SK
J Cancer Res Clin Oncol; 2023 May; 149(5):2139-2155. PubMed ID: 35941226
[TBL] [Abstract] [Full Text] [Related]
4. Inhibitor of the Nuclear Transport Protein xpo1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C-Mutant cancers.
Khan HY; Nagasaka M; Li Y; Aboukameel A; Uddin MH; Sexton R; Bannoura S; Mzannar Y; Al-Hallak MN; Kim S; Beydoun R; Landesman Y; Mamdani H; Uprety D; Philip PA; Mohammad RM; Shields AF; Azmi AS
Cancer Res Commun; 2022 May; 2(5):342-352. PubMed ID: 35573474
[TBL] [Abstract] [Full Text] [Related]
5. Inhibition of xpo1 Sensitizes Small Cell lung cancer to First- and Second-Line Chemotherapy.
Quintanal-Villalonga A; Taniguchi H; Hao Y; Chow A; Zhan YA; Chavan SS; Uddin F; Allaj V; Manoj P; Shah NS; Chan JM; Offin M; Ciampricotti M; Ray-Kirton J; Egger J; Bhanot U; Linkov I; Asher M; Roehrl MH; Qiu J; de Stanchina E; Hollmann TJ; Koche RP; Sen T; Poirier JT; Rudin CM
Cancer Res; 2022 Feb; 82(3):472-483. PubMed ID: 34815254
[TBL] [Abstract] [Full Text] [Related]
6. Impact of xpo1 mutations on survival outcomes in metastatic non-small cell lung cancer (NSCLC).
Nagasaka M; Asad MFB; Al Hallak MN; Uddin MH; Sukari A; Baca Y; Xiu J; Magee D; Mamdani H; Uprety D; Kim C; Xia B; Liu SV; Nieva JJ; Lopes G; Bepler G; Borghaei H; Demeure MJ; Raez LE; Ma PC; Puri S; Korn WM; Azmi AS
Lung Cancer; 2021 Oct; 160():92-98. PubMed ID: 34482103
[TBL] [Abstract] [Full Text] [Related]
7. xpo1 inhibitor KPT-330 synergizes with Bcl-xL inhibitor to induce cancer cell apoptosis by perturbing rRNA processing and Mcl-1 protein synthesis.
Zhu ZC; Liu JW; Yang C; Zhao M; Xiong ZQ
Cell Death Dis; 2019 May; 10(6):395. PubMed ID: 31113936
[TBL] [Abstract] [Full Text] [Related]
8. Analysis of Combined Transcriptomes Identifies Gene Modules that Differentially Respond to Pathogenic Stimulation of Vascular Smooth Muscle and Endothelial Cells.
Pan X; Wang B; Yuan T; Zhang M; Kent KC; Guo LW
Sci Rep; 2018 Jan; 8(1):395. PubMed ID: 29321689
[TBL] [Abstract] [Full Text] [Related]
9. Therapeutic Targeting of Nuclear Export Inhibition in lung cancer.
Gupta A; Saltarski JM; White MA; Scaglioni PP; Gerber DE
J Thorac Oncol; 2017 Sep; 12(9):1446-1450. PubMed ID: 28647672
[TBL] [Abstract] [Full Text] [Related]
10. Overexpression of crm1: A Characteristic Feature in a Transformed Phenotype of lung Carcinogenesis and a Molecular Target for lung cancer Adjuvant Therapy.
Gao W; Lu C; Chen L; Keohavong P
J Thorac Oncol; 2015 May; 10(5):815-825. PubMed ID: 25629636
[TBL] [Abstract] [Full Text] [Related]
11. Antitumor effects of a novel chromosome region maintenance 1 (crm1) inhibitor on non-small cell lung cancer cells in vitro and in mouse tumor xenografts.
Wang S; Han X; Wang J; Yao J; Shi Y
PLoS One; 2014; 9(3):e89848. PubMed ID: 24595136
[TBL] [Abstract] [Full Text] [Related]
